According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier.
As quoted in the Reuters report, Paul Chaplin said that:
We’re looking at late 2016, early 2017 based on potential full data readout.
He also noted that:
There are pre-interim analyses that have been agreed with the FDA (U.S. Food and Drugs Administration). That could, of course, trigger earlier data, but we’re not really guiding when they will occur.
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian Nordic, castration-resistant, mCRPC, metastatic, Prostvac |
THE "NEW" PROSTATE CANCER INFOLINK 
Interested in hearing more.
Data collection was predicted to be complete in December 2015, from details at start of trial. Late 2016 is within range for such a trial for results including statistical data compilation.
Bristol-Myers Squibb made an upfront payment for the option of obtaining Prostvac from Bavarian Nordic. BMS will likely be commercializing Prostvac.